Ultragenyx Pharmaceutical Inc.RARE

時価総額

$31.4億

PER

希少疾患向け医薬品と遺伝子治療の大手。AAVベースの遺伝子治療やASOを含む臨床パイプラインを展開。2022年7月に同業を9,120万ドルで買収。米国を中心に欧州、アジア太平洋で展開、従業員1,294人（2024年12月31日）。

	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-60	-146	-246	-302	-198	-403	-187	-454	-707	-607	-569
Stock-based compensation	-	-	-	-	-	-	86	105	130	135	158
Amortization of premium (discount) on marketable debt securities, net	-4	-6	-5	-2	3	6	-1	-7	-3	13	13
Depreciation and amortization	1	1	3	6	20	9	12	13	18	26	36
Change in fair value of equity investments	-	-	-	-	-	13	170	-42	-19	0	-1
Non-cash collaboration royalty revenue	-	-	-	-	-	-	13	18	22	69	101
Non-cash interest expense on liabilities for sales of future royalties	-	-	-	-	-	1	33	29	43	66	63
Other	-	-	-	-	0	-1	-1	-0	0	-2	3
Accounts receivable	-	-	-	-	8	20	-10	5	12	23	34
Inventory	-	-	-	-	5	4	1	3	10	7	11
Prepaid expenses and other assets	-	-	-	-	-	-	-	-	-	-	-12
Other assets	-	-	-	-	-	-	-	-	-	-15	-
Accounts payable, accrued, and other liabilities	-	-	-	-	-	13	27	32	87	2	47
Deferred tax liabilities	-	-	-	-	-	2	-	-	-2	-2	-
Net cash used in operating activities	-	-	-	-	-291	-345	-132	-339	-380	-475	-414
Purchase of property, plant, and equipment	2	5	10	3	4	25	44	73	116	44	7
Acquisition, net of cash acquired	-	-	-	143	-	-	-	-	75	-	-
Purchase of marketable debt securities	-	-	-	-	-	-	813	1,012	615	526	409
Proceeds from sale of marketable debt securities	-	-	-	-	-	-	51	93	84	51	3
Proceeds From Sale Of Equity Investment	-	-	-	-	-	-	80	80	10	-	-
Proceeds from maturities of marketable debt securities	83	249	403	274	303	676	590	718	451	696	410
Payment for intangible asset	-	-	-	-	-	-	-	-	30	3	13
Other	-	-	-	-	-	-	6	1	1	5	2
Net cash (used in) provided by investing activities	-	-	-	-	-33	-13	-179	-195	-292	168	-18
Proceeds from the sale of future royalties, net	-	-	-	-	-	314	-	-	491	-	-
Proceeds from the issuance of common stock and pre-funded warrants in connection with underwritten public offerings, net of issuance costs	-	-	-	-	-	-	-	-	-	326	381
Proceeds from the issuance of common stock in connection with at-the-market offering, net of issuances costs	-	-	-	-	-	-	-	-	-	53	-
Proceeds from the issuance of common stock from exercise of equity plan awards, net	-	-	8	9	28	10	89	40	11	8	11
Proceeds from Noncontrolling Interests	-	-	-	-	-	-	-	-	-	-	7
Other	-	-	-	-	-	-	-0	-0	-1	-0	-
Net cash provided by financing activities	-	-	-	-	337	679	600	119	501	388	399
Effect of exchange rate changes on cash	-	-	-	-	-0	-0	1	-1	-1	0	-3
Net (decrease) increase in cash, cash equivalents, and restricted cash	-	-	-	-	12	321	290	-417	-172	82	-35
Acquired lease liabilities arising from obtaining right-of-use assets and property, plant, and equipment	-	-	-	-	-	-	-	-	-	22	10
Capital Expenditures Incurred but Not yet Paid	-	1	0	0	1	10	9	19	18	2	1
Non-cash interest expense on liability related to the sale of future royalties capitalized into ending property, plant and equipment	-	-	-	-	-	-	-	5	11	9	-